KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Nov 20, 2026 >>  ABB India 6915  [ -0.62% ]  ACC 1276.45  [ 0.65% ]  Ambuja Cements 399.3  [ 0.58% ]  Asian Paints 2603.35  [ 0.37% ]  Axis Bank 1447  [ 2.05% ]  Bajaj Auto 10778  [ -0.34% ]  Bank of Baroda 286.6  [ 0.39% ]  Bharti Airtel 2155.5  [ 0.39% ]  Bharat Heavy 433  [ -0.23% ]  Bharat Petroleum 312  [ 1.46% ]  Britannia Industries 4890  [ 0.42% ]  Cipla 1414.95  [ -0.07% ]  Coal India 390  [ -0.51% ]  Colgate Palm 1760.6  [ -0.81% ]  Dabur India 394  [ 0.77% ]  DLF 783.5  [ 2.14% ]  Dr. Reddy's Lab. 1390.5  [ -0.54% ]  GAIL (India) 191.45  [ -0.21% ]  Grasim Industries 3102.4  [ -0.07% ]  HCL Technologies 1337  [ 0.41% ]  HDFC Bank 845.25  [ 3.02% ]  Hero MotoCorp 5523  [ -0.59% ]  Hindustan Unilever 2054  [ -0.96% ]  Hindalco Industries 930.3  [ 2.34% ]  ICICI Bank 1641  [ 2.22% ]  Indian Hotels Co. 911.55  [ 2.22% ]  IndusInd Bank 1005  [ 8.88% ]  Infosys 1096.4  [ 0.54% ]  ITC 298.8  [ -0.73% ]  Jindal Steel 1125.35  [ 4.31% ]  Kotak Mahindra Bank 516  [ 3.08% ]  L&T 4201  [ -0.10% ]  Lupin 2010  [ 0.55% ]  Mahi. & Mahi 3541.5  [ 0.89% ]  Maruti Suzuki India 13990.3  [ 2.88% ]  MTNL 24.28  [ -2.18% ]  Nestle India 1326  [ 1.58% ]  NIIT 69.47  [ -0.97% ]  NMDC 69  [ 1.16% ]  NTPC 320.8  [ -1.29% ]  ONGC 223.5  [ -0.45% ]  Punj. NationlBak 155.2  [ -0.13% ]  Power Grid Corpn. 268.5  [ 1.70% ]  Reliance Industries 1375.1  [ 0.37% ]  SBI 1164.95  [ 0.60% ]  Vedanta 237.6  [ -2.38% ]  Shipping Corpn. 256.7  [ 2.87% ]  Sun Pharmaceutical 1885.1  [ -0.94% ]  Tata Chemicals 639.15  [ -1.64% ]  Tata Consumer 1155  [ 1.18% ]  Tata Motors Passenge 266.05  [ 1.04% ]  Tata Steel 177.75  [ -1.69% ]  Tata Power Co. 340  [ 0.00% ]  Tata Consult. Serv. 2375  [ 1.21% ]  Tech Mahindra 1742  [ 1.10% ]  UltraTech Cement 12926.4  [ 2.75% ]  United Spirits 1461  [ -0.27% ]  Wipro 185.5  [ 0.60% ]  Zee Entertainment 71.4  [ -0.07% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

PANACEA BIOTEC LTD.

20 November 2026 | 12:00

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE922B01023 BSE Code / NSE Code 531349 / PANACEABIO Book Value (Rs.) 136.66 Face Value 1.00
Bookclosure 27/09/2024 52Week High 647 EPS 0.00 P/E 0.00
Market Cap. 2057.72 Cr. 52Week Low 292 P/BV / Div Yield (%) 2.46 / 0.00 Market Lot 1.00
Security Type Other

NOTES TO ACCOUNTS

You can view the entire text of Notes to accounts of the company for the latest year
Year End :2026-03 

s. Provisions, contingent liabilities and contingent assets

Provisions are recognised when present obligations as a result of past events will probably lead to an outflow of economic
resources from the Company and they can be estimated reliably. Timing or amount of the outflow may still be uncertain. A
present obligation arises from the presence of a legal or constructive obligation that has resulted from past events.

Provisions are measured at the best estimate of expenditure required to settle the present obligation at the reporting date,
based on the most reliable evidence, including the risks and uncertainties associated with the present obligation.

In those cases where the possible outflow of economic resource as a result of present obligations is considered improbable or
remote, or the amount to be provided for cannot be measured reliably, no liability is recognised in the balance sheet.

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be
confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of
the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources
will be required to settle the obligation or a reliable estimate of the amount cannot be made. The Company does recognise a
contingent liability but discloses its existence in the financial statements.

Any amount that the Company can be virtually certain to collect from a third party with respect to the obligation is recognised
as a separate asset up to the amount of the related provisions. All provisions are reviewed at each reporting date and adjusted
to reflect the current best estimate.

Contingent assets are not recognized in the financial statements.

t. Exceptional Items

An item of income or expense which by its size, type or incidence requires disclosure in order to improve an understanding of
the performance of the Company is treated as an exceptional item and the same is disclosed in standalone statement of profit
and loss and in the notes forming part of the standalone financial statements.

1.4 Critical management judgments in applying accounting policies and estimation uncertainty

The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions
that affect the reported amounts of revenues, expenses, assets and liabilities and the related disclosures.

Judgments

Research and developments costs: Management monitors progress of internal research and development projects by using
a project management system. Significant judgment is required in distinguishing research from the development phase.
Development costs are recognised as an asset when all the criteria are met, whereas research costs are expensed as incurred.
Management also monitors whether the recognition requirements for development costs continue to be met. This is necessary
due to inherent uncertainty in the economic success of any product development.

Recognition of deferred tax assets: The extent to which deferred tax assets can be recognized is based on an assessment of the
probability of the future taxable income against which the deferred tax assets can be utilised.

Provisions, contingent liabilities and contingent assets: The Company is the subject of legal proceedings and tax issues covering
a range of matters, which are pending in various jurisdictions. In view of the uncertainty inherent in such matters, it is difficult to

predict the final outcome of such matters. The cases and claims against the Company often raise difficult and complex factual and
legal issues, which are subject to many uncertainties, including but not limited to the facts and circumstances of each particular
case and claim, the jurisdiction and the differences in applicable law. In the normal course of business, management consults
with legal counsel and certain other experts on matters related to litigation and taxes. The Company accrues a liability when it is
determined that an adverse outcome is probable and the amount of the loss can be reasonably estimated.

Impairment of financial assets: At each balance sheet date, based on historical default rates observed over expected life, the
management assesses the expected credit loss on outstanding financial assets.

Evaluation of indicators for impairment of assets: The evaluation of applicability of indicators of impairment of assets requires
assessment of several external and internal factors which could result in deterioration of recoverable amount of the assets.

Estimates

Useful lives of depreciable / amortisable assets: Management reviews its estimate of the useful lives of depreciable/amortisable
assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical and
economic obsolescence that may change the utility of certain software, IT equipment and other plant and equipment.

Defined benefit obligation: Management's estimate of the Defined Benefit Obligations (DBO) is based on a number of critical
underlying assumptions such as standard rates of inflation, mortality, discount rate and anticipation of future salary increases.
Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.

Fair value measurements

Management applies valuation techniques to determine the fair value of financial instruments (where active market quotes are
not available). This involves developing estimates and assumptions consistent with how market participants would price the
instrument.

1.5 New and amended standards

The Company has applied the following amendments for the first time for their annual reporting period commencing 1 April 2023:

Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors: The amendments to Ind AS 8 clarify the distinction
between changes in accounting estimates, changes in accounting policies and the correction of errors. They also clarify how
entities use measurement techniques and inputs to develop accounting estimates. The amendments had no impact on the
Company's standalone financial statements.

Ind AS 1 - Presentation of Financial Statements: The amendments to Ind AS 1 provide guidance on applying materiality judgements
to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful
by replacing the requirement for entities to disclose their 'significant' accounting policies with a requirement to disclose their
'material' accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about
accounting policy disclosures.

The amendments have had an impact on the Company's disclosures of accounting policies, but not on the measurement,
recognition or presentation of any items in the Company's financial statements.

Ind AS 12 - Income Taxes: The amendments to Ind AS 12 Income Tax narrow the scope of the initial recognition exception, so that
it no longer applies to transactions that give rise to equal taxable and deductible temporary differences such as leases. The above
amendments did not have any material impact on the amounts recognised in prior periods and are not expected to significantly
affect the current or future periods.

1.6 Recent accounting pronouncements:

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian
Accounting Standards) Rules as issued from time to time. MCA has issued following amendments:

Amendment to Ind AS 1 'Presentation of Financial Statements'- Classification of Liabilities as current or non-current and non¬
current liabilities with covenants. The amendment includes specific provisions that will take effect for reporting periods beginning
on or after April 01,2026, retrospectively, as outlined below:

(i) Breach of material covenant for long-term loan arrangement on or before the end of reporting period with the effect that
liability becomes payable on demand as on reporting date, then it shall be classified as current liability, if lender agreed after
reporting period and before approval of standalone financial statements to not demand payment as a consequence of breach.

(ii) Classify as non-current liability, if lender agreed by the end of reporting period to provide grace period ending at least 12
months after reporting period within which entity can rectify the breach provided lender does not demand immediate
repayment.

(iii) Disclose information about the timing of settlement to understand the impact of the liability on the standalone financial
statements.

The Company does not expect this amendment to have an impact on its operations or standalone financial statements.

(i) Refer note 37(B) for information on contractual commitments related to property, plant and equipment.

(ii) During financial year ended March 31, 2025, the Company has classified its properties amounting ?35.00 million (Gross value ?40.80 million and accumulated
depreciation ?5.80 million) as investment property from property plant and equipment, due to change in plan and objective towards utilisation of said
properties.

(iii) During financial year ended March 31, 2026, the Company has classified its properties amounting ?13.45 million (Gross value ?16.99 million and accumulated
depreciation ?3.54 million) as investment property from property, plant and equipment, due to change in plan and objective towards utilisation of said
properties.

(iv) The Company carried out an impairment assessment of the cash-generating unit (CGUs) in terms of Ind AS 36 "Impairment of Assets" using a discounted cash flow
model which is based on the net present value of the forecasted earnings of the CGUs with the help of an external valuation specialist. This is calculated using
certain assumptions viz. discount rate of 13.78%, terminal year growth rate of 4% and cash flow forecasts for 5 years. The Company has also involved independent,
registered valuer to assess the value in use of the CGUs by cash flow approach. These forecasts contain management's best view of the expected performance of
the CGU based on the management's knowledge of the market environment, strategic initiatives and future business plans. As per the management's assessment,
there is no impairment required to be recognized in the statement of profit and loss account.

(v) The Company has not revalued its property, plant and equipment during the financial year 2025-26 and 2024-25.

(vi) The Company has adopted cost model for its property, plant and equipment.

(b) Terms / rights attached to equity shares:

The Company has only one class of equity shares having a par value of ?1 per share. Each holder of equity shares is entitled to one vote per
share. The Company declares and pays dividends in Indian Rupees. The dividend if any, proposed by the Board of Directors is subject to the
approval of the shareholders in the ensuing Annual General Meeting. The Board of Directors has not proposed any dividend on equity shares
for current year and previous year.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after
distribution of all preferential amounts including preference shares. The distribution will be in proportion to the number of equity shares held
by the equity shareholders.

The Company has not reserved any shares for issuance under options.

Notes:

i) Includes income tax demand of ?99.52 million in respect to Assessment Year 2005-06. The Income Tax Department had issued alleged demand
based on certain grounds related to purchases made by the Company from an overseas vendor. The matter was decided in favour of the
Company and the demand was cancelled by Commissioner of Income Tax (Appeals) ("CIT (Appeals)"). However, the Income Tax Department
filed an appeal before Income Tax Appellate Tribunal ('ITAT') against the order of CIT (Appeals). During the financial year 2025-26 the same
has been allowed in favour of the Company. Keeping in view that the stipulated period for filing of appeal by the Income Tax department
against the said order of the Hon'ble ITAT is not yet over, the management has decided to continue to show the amount as a contingent
liability.

ii) A search operation was conducted by the Income Tax Department in the premises of the Company in January 2012 and hence the Company
re-filed the income tax returns for the Assessment Year 2006-07 to 2012-13. During the year ended March 31,2015, the Income Tax Department
completed the assessment of the said years, disallowed certain expenses and issued demand of ?3,294.90 million (including interest) on various
grounds. The Company preferred appeals before the CIT (Appeals) against the orders of the Income Tax Department. The appeals were decided
in favour of the Company and the demand was cancelled. However, CIT (Appeals) made certain disallowances with respect to Assessment Year

2010- 11 and 2011-12 against which the Company filed appeals before the (ITAT). The Income Tax Department also filed appeal before ITAT
against the orders of CIT (Appeals). During the financial year 2025-26, the Hon'ble ITAT has, vide its consolidated Order dated February 27, 2026
(a) dismissed all seven appeals filed by the Income Tax Department against the orders of the CIT (Appeals) for Assessment Years 2006-07 to
2012-13; (b) allowed both appeals filed by the Company against the CIT (Appeals) orders dated July 27, 2015, for Assessment Years 2010-11 and

2011- 12; and quashed the underlying assessment orders passed by the Assessing Officer / DCIT for Assessment Years 2006-07 to 2012-13, thereby
providing complete relief to the Company. Keeping in view that the stipulated period for filing of appeal by the Income Tax Department against
the said order of the Hon'ble ITAT is not yet over, the management has decided to continue to show this amount as a contingent liability.

iii) The Income Tax Department had raised a demand of ?33.69 million in respect of Assessment Year 2016-17 based on transfer pricing order
passed by Dispute Resolution Panel. The alleged demand was raised on purchase of certain goods by the Company from its associated
enterprise wherein, according to Income Tax Department, arms' length price adjustment was warranted. The Company filed appeal before
ITAT against the order passed by the Income Tax Department. During financial year 2023-24, the said appeal has been decided in favour of the
Company. Further, the department has filed an appeal before the Hon'ble Delhi High court, against the order of the Hon'ble ITAT. Based on legal
advice, the Company believes that it has merits in this case, hence no provision is required.

iv) The Income Tax Department has levied a penalty of ?93.88 million in respect of Assessment Years 2017-18, 2020-21 & 2021-22 on account of
alleged under reporting of income in assessment orders passed for the said years. The Company filed an appeal before CIT (Appeals) against
the order passed by the Income Tax Department but the same was dismissed by the CIT (Appeals). The Company has filed an appeal before the
Hon'ble ITAT against the order passed by the CIT (Appeals). Based on legal advice, the Company believes that it has merits in these cases, hence
no provision is required.

v) The Income Tax Department had raised a demand of ?2,620.80 million in respect of Assessment Year 2020-21. The alleged demand was raised
due to wrong addition of contingent liability not provided for, set-off of business losses not allowed and increase in other income due to set¬
off of business losses not allowed. The Ccompany filed an appeal before CIT (Appeals) and rectification application before assessing officer
against the order passed by the Income Tax Department. During the financial year 2023-24, while the said appeal was under consideration,
the assessing officer has passed rectification order in favour of the Company and reduced the said tax demand to ?91.63 million. The Company
believes that it has merits in this case, hence no provision is required.

vi) The Income Tax Department has raised a demand of ?0.86 million in respect of Assessment Year 2018-19 on the ground of alleged non-

deduction of withholding tax on certain foreign remittances made by the Company. The Company has filed an appeal before CIT (Appeals)
against the order passed by the Income Tax Department and the same was dismissed by the CIT (Appeals). The Company has filed an appeal
before the Hon'ble ITAT against the order passed by the CIT (Appeals). Based on legal advice, the Company believes that it has merits in this
case, hence no provision is required.

vii) Service tax and Excise & Custom duty litigations with respect to disallowance of input tax credit, rebate claim and levy of service tax are
pending with various authorities. The Company believes that it has merit in these cases and hence no provision is required.

viii) The Company had manufactured and offered supply of certain vaccines which were manufactured against the confirmed order received from
the Ministry of Health and Family Welfare ("MOHFW"), Govt. of India. Some quantities of vaccines were supplied during December 2011, the
balance could not be supplied in view of disputes with respect to delivery dates and in the meantime the stock of such vaccines amounting
to ?74.10 million expired. Further, the Company also received an advance market commitment ("AMC") amounting to ?100.00 million towards
against these vaccines. The refund of the advance so received (after adjusting the amount receivable against the vaccines already supplied)
was demanded back by MOHFW along with interest on account of non-supply of balance quantities of vaccines. In view of above disputes, the
Company obtained a stay order from the Hon'ble Delhi High Court against recovery of said amount, till the disputes are finally resolved through
arbitration. The arbitration award was pronounced in favour of the Company on March 14, 2019, vide which MOHFW was directed to pay the
applicable amount for vaccine supplied / offered for supply along with interest. MOHFW filed an appeal before Hon'ble Delhi High Court raising
certain objections against the award, which was dismissed by the Hon'ble Court. MOHFW filed an appeal against such order before the Division
Bench of the Hon'ble Delhi High Court which was also rejected. MOHFW has filed a Special Leave Petition against such order before the Hon'ble
Supreme Court of India. The same is currently pending before Hon'ble Supreme Court of India. The Company's application for execution of
award is also currently pending before the Hon'ble Delhi High Court. The Company believes that it has merits in this case and the outcome of
this matter will not have any material adverse impact on the financial position of the Company.

ix) In March 2024, the Company received summons from Asst. Commissioner of State Tax ("ACST”), Mumbai to enquire if the Company had paid
GST on sale of the leasehold land and building at Navi Mumbai in March 2022. The Company's officials attended the proceedings and clarified
that the GST was not applicable as the said transaction was covered under Schedule III to CGST / MGST Act. However, following persistent
follow-up by the GST authorities, the Company deposited an amount of ?31.42 million under protest. The Company filed a writ petition before
the Hon'ble High Court of Judicature at Bombay against the said proceedings. The Hon'ble High Court has set aside the demand order on
January 22, 2025 and the matter was remanded back to the ACST, Mumbai for a fresh adjudication on the show cause notice. The Hon'ble High
Court also directed the ACST, Mumbai to take into consideration and deal with the recent decision of the Gujarat High Court on a similar issue
whilst rendering its findings on the show cause notice. Subsequently, ACST, Mumbai issued a fresh demand order of ?70.34 million (including
interest and penalty) after adjusting ?31.42 million deposited under protest. The Company has again filed a writ petition before the Hon'ble
High Court. The Hon'ble High Court has passed interim order stating that no recovery proceedings shall be initiated against the Company and
the final order is yet to be passed. The Company believes that the Company has merits in its case and hence the Company has not made any
provision in respect of this matter.

x) In December 2023, the Company received a demand order from State Tax Officer, Kerala raising demand of ?1.75 million (including penalty
and applicable interest) for financial year 2017-18 rejecting the Company's claim for input tax credit on account of non-submission of relevant
documents. The Company has filed an appeal on February 02, 2024 before the Appellate Authority which is pending. The Company believes
that it has merit in this case and hence no provision is required.

xi) In February 2025, the Company received a demand order from Superintendent, Central Goods & Services Tax, Derabassi-I, Punjab raising
demand of ?0.33 million (including penalty) and applicable interest for financial year 2020-21 on account of alleged excess claim of input credit
w.r.t. import of goods. The Company has filed an appeal before the Appellate Authority against the aforesaid demand order on April 26, 2025.
The Company believes that it has merit in this case and hence no provision is required.

xii) In September 2025, the Company has received show cause notice from Assistant Commissioner, Central GST (Audit), Ludhiana, Punjab for
financial years 2019-20 to 2021-22 demanding GST of ?228.81 million and applicable interest on corporate guarantee of ?8,640.00 million
provided by the Company in favour of its WOS Panacea Biotec Pharma Limited. The Company has filed a Writ Petition before the Hon'ble
Punjab & Haryana High Court. The Hon'ble High Court has, vide its order dated January 1,2026, held that no coercive action be taken against
the Company in case final assessment order is passed or a demand is raised. The Additional Commissioner, CGST Sub-Commissionerate, Mohali
has issued a demand order dated March 30, 2026 confirming the aforesaid demand. The Company has filed an appeal against the said demand
order before the Appellate Authority. The Company believes that the Company has merit in its case and hence the Company has not made any
provision in respect of this matter.

xiii) In December 2025, the Company has received a demand order from Commercial Tax Officer, Tamil Nadu raising a demand of ?0.51 million
(including penalty and interest) for financial year 2021-22 on account of alleged short payment of tax liability. The Company has filed an appeal
against the order before the Appellate Authority on March 25, 2026. The Company believes that it has merit in this case and hence no provision
is required.

xiv) With respect to the 4 old labour cases pending before the Presiding Officer, Industrial Tribunal, Mohali in respect of manufacturing facility of
the Company at Lalru, Punjab, during financial year 2024-25, the Company initiated settlement process and recognised an amount of ?42.80
million as the compensation payable in respect of these cases, out of which ?22.51million has been paid as on March 31, 2026 (March 31,
2025: ?18.51 million) and the balance amount has been included as a liability in the financial statements. The Company has received 4 awards
dated March 19, 2026, whereby the Tribunal has, inter-alia, set aside transfer of 23 workmen and granted relief of full back wages from the
date of transfer; awarded reasonable wage revision for the workmen; and awarded reinstatement of the workers (other than those who have
settled the dispute) with 50% back wages from the date of termination. The Company believes that it has merits in these cases. The Company
is therefore filing appeals against the aforesaid awards before the Hon'ble Punjab and Haryana High Court, Chandigarh. Accordingly, the
Company has not made any provisions in respect of these matters. In view of large number of other cases, it is impracticable to disclose each
case.

38. Leases

Company as a lessee:

The Company does not have any long-term non cancellable leases during the current and previous financial year. As on April 1, 2019, leasehold
land has been transferred to Right of Use ("RoU") asset. Refer note 2.1 for details.

Lease payments with respect to short term lease amounts to ?37.34 million (March 31,2025: ? 28.76 million).

Company as a lessor:

Operating leases

The Company has entered into operating leases on its investment property portfolio consisting of certain offices, guest house, warehouse,
manufacturing buildings etc. These leases generally have terms of 11 months. All leases generally include a clause for upward revision of the rental
charge by 5% on an annual basis according to prevailing market conditions. Rental income recognised by the Company from above said lease
agreements is ?48.54 million (March 31,2025: ?45.42 million).

C. Defined contribution plans

The Company's contribution to state governed provident fund, employees' state insurance and labour welfare fund schemes are considered
as defined contribution plans. The contribution for the current year is ?27.00 million (March 31,2025: ?25.51 million) and under the schemes
is recognised as an expense, when an employee renders the related service. There are no other obligations of the Company, other than the
contribution payable to the respective funds.

B.2 Financial assets and liabilities are measured at amortised cost. All the financial assets and liabilities valued at amortised cost form part of Level 3
of hierarchy table. Further, the carrying amounts of trade receivables, cash and cash equivalents, consignment debtors, interest accrued, other
receivables, other bank balances, trade payables, employee payables and other current payables are considered to be the same as fair values,
due to their short term nature. The fair value of all financial assets and financial liability, approximates the amortised cost due to their short term
nature. They are classified as level 3 fair value in the fair value hierarchy due to the inclusion of unobservable inputs, including own credit risk.
The fair value of loans to employees and security deposits approximates the carrying amount.

Risk management framework

The Company's activities expose it to market risk, liquidity risk and credit risk. The management has the overall responsibility for the establishment
and oversight of the Company's risk management framework. This note explains the sources of risk which the entity is exposed to and how the
entity manages the risk and the related impact in the financial statements.

A. Credit risk

Credit risk is the risk that a counter party fails to discharge its obligation to the Company. The Company's exposure to credit risk is influenced
mainly by cash and cash equivalents, trade receivables and financial assets measured at amortised cost. The Company continuously monitors
defaults of customers and other counter parties and incorporates this information into its credit risk controls.

A.1 Credit risk management

The Company assesses and manages credit risk based on internal credit rating system. Internal credit rating is performed for each class of
financial instruments with different characteristics. The Company assigns the following credit ratings to each class of financial assets based on
the assumptions, inputs and factors specific to the class of financial assets:

A: Low credit risk on financial reporting date
B: Moderate credit risk
C: High credit risk

Cash and cash equivalents and bank deposits: Credit risk related to cash and cash equivalents and bank deposits is managed by only accepting
highly rated banks and diversifying bank deposits and accounts in different banks across the country.

Trade receivables: Credit risk related to trade receivables are mitigated by taking bank guarantees / letter of credit, from customers where
credit risk is high. The Company closely monitors the credit-worthiness of the debtors through internal systems that are configured to define
credit limits of customers, thereby limiting the credit risk to pre-calculated amounts. The Company assesses increase in credit risk on an
ongoing basis for amounts receivable that become past due and default is considered to have occurred when amounts receivable become
two year past due.

Other financial assets measured at amortised cost: Other financial assets measured at amortized cost includes security deposits and other
Credit risk related to these other financial assets is managed by monitoring the recoverability of such amounts continuously.

The Company provides for expected credit losses on loans and advances other than trade receivables by assessing individual financial
instruments for expectation of any credit losses. Since the Company deals with only high-rated banks and financial institutions, credit risk in
respect of cash and cash equivalents, other bank balances and bank deposits is evaluated as very low. In respect of loans, comprising of security
deposits, credit risk is considered low because the Company is in possession of the underlying asset. However, in respect of loans comprising
loans to related parties, credit risk is evaluated on the basis of credit worthiness of those parties and loss allowance is measured as lifetime
expected credit losses. In respect of other financial assets, credit risk is evaluated based on Company's knowledge of the credit worthiness
of those parties and loss allowance is measured as lifetime expected credit losses. The Company does not have any expected loss based
impairment recognised (except in case of loans to related parties) on such assets considering their low credit risk nature, though incurred loss
provisions are disclosed under each sub-category of such financial assets.

A.3 Expected credit loss for trade receivables under simplified approach

The Company recognizes lifetime expected credit losses on trade receivables using a simplified approach, wherein the Company has
defined percentage of provision by analysing historical trend of default relevant to each category of customer based on the criteria defined
above and such provision percentage determined have been considered to recognise life time expected credit losses on trade receivables
(other than those where default criteria are met). The Company has other trade receivables for ?172.30 million (March 31, 2025: ?184.26
million) against which it is carrying unsecured payables for corresponding amount for whose default criteria are not met and are not
included in the below table.

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are
settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure as far as possible, that it will
have sufficient liquidity to meet its liabilities when they are due. The Company manages its liquidity needs by carefully monitoring scheduled
debt servicing payments for long-term financial liabilities as well as cash outflows due in day-to-day business. Long-term liquidity needs for a
180-day and a 360-day lookout period are identified monthly.

Management monitors rolling forecasts of the liquidity position and cash and cash equivalents on the basis of expected cash flows. The
Company takes into account the liquidity of the market in which the entity operates.

B.1 Contractual maturities of financial liabilities

The tables below analyse the Company's financial liabilities based on their contractual maturities. The amounts disclosed in the table are the
contractual undiscounted cash flows.

C. Market risk

(i) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest
rates. The Company's exposure to the risk of changes in market interest rate related primarily to the Company's non-current and current
debt obligations financed with fixed interest rate. The Company always try to ensure minimum cash outlfows. The assumed movement
in basis points for the interest rate sensitivity analysis is based on the currently observable market environment, showing a significantly
higher volatility. Accordingly, the Company is not exposed to fluctuations in interest rate risk on borrowings.

The Company is exposed to foreign exchange risk arising from foreign currency transactions, primarily with respect to the United State
Dollar (USD), Euro, Swiss Frank (CHF), Pound Sterling (GBP), Swedish Krona (SEK) and Singapore Dollar (SGD). Foreign exchange risk arises
from recognised assets and liabilities denominated in a currency that is not the functional currency of the Company. The Company does
not use any derivative instruments to manage its exposure. Also, the Company does not use forward contracts and swaps for speculative
purposes.

The Company's capital management objectives are to ensure the Company's ability to continue as a going concern as well as to provide an
adequate return to shareholders by pricing products and services commensurately with the level of risk.

The Company monitors capital on the basis of the carrying amount of equity plus its subordinated loan, less cash and cash equivalents as presented
on the face of the statement of financial position recognised in other comprehensive income.

The Company manages its capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics
of the underlying assets. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders,
return capital to shareholders or issue new shares. The Company is not subject to any externally imposed capital requirements. The amounts
managed as capital by the Company are summarised as follows:

47. The Board of Directors of the Company and Panacea Biotec Pharma Limited ("PBPL") had in their respective meetings held on February 01,
2022, approved sale of PBPL's pharmaceutical formulations brands in India and Nepal including related trademarks, copyrights etc., including
identified employees to Mankind Pharma Limited (the "Buyer”) for a consideration of ?18,720.00 million plus applicable taxes. The said
transaction was approved by the shareholders of PBPL and the Company in their respective meetings held on February 23, 2022 and February
26, 2022, respectively. Subsequently, the Company and PBPL signed definitive agreements including the asset purchase agreement with the
Buyer on February 28, 2022. Out of the total consideration, PBPL has recognised revenue of ?109.25 million (March 31, 2025: ?359.94 million)
which is shown as an "Exceptional Item” in the Statement of Profit and Loss of PBPL and Consolidated Statement of Profit and Loss of the
Group. The remaining consideration of ?101.80 million (March 31,2025: ?211.05 million) would be recognised as revenue in subsequent years
and is shown as Contract Liability in the financial statements of PBPL and consolidated financial statements of the Group. Further, revenue of
?85.71 million (year ended March 31,2025: ? Nil) is also shown as "Exceptional item" pursuant to the settlement agreement dated July 09, 2025
executed with Apotex Inc. USA ("Apotex") to settle the ongoing dispute between Apotex and the Company & PBPL.

48. For the financial year ended March 31, 2026, the Company has incurred loss (including other comprehensive income) of ?287.60 million (year
ended March 31, 2025: loss of ?151.74 million) and as on March 31, 2026, the retained earnings of the Company are negative to the extent
of ?2,178.43 million (March 31,2025: ?1,890.83 million). The aforesaid conditions indicate the existence of uncertainty that may create doubt
about the Company's ability to continue as a going concern. However, the retained earnings of the Group are positive to the extent of ?7,760.55
million (March 31,2025: ?7,799.13 million). The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands
in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of
capacities for manufacturing of vaccines drug substance, scaling up Group's nutrition and pharmaceutical formulations business and pursuing
other business opportunities. The Company has already received higher long-term awards from United Nations International Children's Fund
(UNICEF) and Pan American Health Organisation (PAHO) for supply of pentavalent vaccine and awards from UNICEF for supply of bivalent oral
polio vaccine. Based on these measures and continuous efforts to improve the business performance, the management has prepared the
financial statements on going concern basis.

49. (a) In view of the Company's decision to make the structure of overseas subsidiaries more efficient and aligned to business objectives and to

save management and administrative expenses thereof, the Company has decided to wind up Panacea Biotec (International) SA ("PBS”)
in due course. Accordingly, the Company has created provision for impairment on its investment in PBS. Owing to accumulated losses in
PBS and its wholly owned subsidiary, Panacea Biotec Germany GmbH ("PBGG"), the Company has continued to maintain the provision for
bad and doubtful advances in respect of the loans receivable and accrued interest from PBS and PBGG amounting to ?156.92 million and
?518.07 million, respectively, as on March 31, 2026 (March 31,2025: ?139.00 million and ?458.90 million, respectively).

(b) The Company has applied with the authorized dealer bank to seek permission from Reserve Bank of India for writing off an amount of
?585.16 million which was receivable from the Company's wholly owned subsidiary Rees Investments Ltd. ("Rees"), which was compulsorily
liquidated and dissolved by the authorities of Guernsey on May 23, 2019. Pending such approval, the Company is continuing to maintain
the provision for bad and doubtful advances of ?585.16 million (March 31,2025: ?585.16 million) in respect of the loan and accrued interest
receivable from Rees.

50. Under the collaboration with the Human Vaccine Limited Liability Company, Russia ("HV”), an indirect wholly owned subsidiary of Joint
Stock Company "Management Company of Russian Direct Investment Fund” for manufacture of Covid-19 vaccine using the technology to
be provided by HV, the Company had received from HV an advance amount of US$ 7.00 million in November 2020, out of which ~US$ 6.58
million was used to meet the revenue expenses relating to Sputnik-V and Sputnik Light vaccine project. The Company believes that due
to the failure on the part of HV to demonstrate & transfer the technology and certain other reasons beyond the Company's control, the
complex process of technology transfer and manufacture of Sputnik-V vaccine could not be completed successfully and the Technology
Transfer Agreement dated October 22, 2020 entered into between HV and the Company ("TTA”) for manufacturing of Covid-19 vaccine
stood frustrated and accordingly both the parties stood automatically discharged from their obligations by operation of law. The Company
is thus entitled to adjust the same against the advance received from HV. The Company has already conveyed its position to HV and has
offered to refund the balance amount of US$ 0.42 million and provided relevant details / documents pertaining to the said expenses. On
July 1, 2024, the Company received a copy of Request for Arbitration filed by HV with London Court of International Arbitration ("LCIA”) for
initiating arbitration alleging that the Company has been in alleged breach of its obligations under the TTA and is thus liable to refund the
advance payment of US$7.00 million plus interest thereon as may be awarded over the course of arbitration. Both parties have appointed
the sole arbitrator in this matter. The Company is taking requisite steps to safeguard its interest and has filed its response along with witness
statements and counter claims against HV. Further arbitration proceedings, including cross examinations etc. shall be completed in due
course. Based on the Company's assessment, duly supported by legal advice, the Company believes that it will not be liable to pay back
the amount adjusted towards wasted expenses and costs under dispute with HV and the outcome of this arbitration proceeding is not
reasonably expected to have any material financial impact on the Company.

51. In August 2021, the Company had entered into a Licensing and Manufacture Agreement with HV, Generium JSC and Dr. Reddy's Laboratories
Limited ("DRL"). As per the terms of the agreement, the Company was to undertake fill-and-finish activities of Sputnik-V vaccine using the
ready-to-fill drug substance supplied by Generium and supply the Sputnik-V vaccine so produced to DRL. Pursuant to the said agreement, the
Company received drug substance from Generium and produced ~1.96 million doses of Sputnik-V vaccine out of which DRL purchased ~0.86
million doses only and refused to purchase and pay for the remaining ~1.10 million doses. Because of breach of their respective obligations by
DRL and Generium, the pending payment of ~US$ 7.41 million for the drug substance received from Generium could not be made. After several
rounds of discussion among the parties to settle the dispute amicably, Generium has filed notice of arbitration with Singapore International
Arbitration Centre (SIAC) for arbitration of dispute with respect to the said pending payment and interest thereon totalling ~US$ 8.90 million.
The Company has also initiated a parallel arbitration proceeding regarding its claims against DRL, Generium and Human Vaccine and filed
notice of arbitration with SIAC during the financial year 2023-24. At the Company's request, SIAC has clubbed both the arbitration proceedings
together. The parties have appointed sole arbitrator. All the parties involved in the Arbitration have filed claims and counter claims against each
other. The witness statements, cross examination and closing submissions have been completed and the arbitration award is now awaited. The
Company has obtained legal opinion from its legal counsel who, have opined that (a) the Company has a reasonable defence against the claims
brought by Generium, DRL and HV; and (b) the possibility of any such claim falling to the Company may be classified as low at this stage.

52. Additional regulatory information required by Schedule III under Companies Act 2013:

(i) The Company does not have any Benami Property, where any proceeding has been initiated or pending against the Company for holding any
Benami property.

(ii) The Company does not have any transactions with stuck off companies.

(iii) The Company does not have any charges or satisfaction of charge which is yet to be registered with Registrar of Companies beyond the
statutory period.

(iv) The Company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

(v) The Company has not advanced or loaned to, or invested funds in, any other person(s) or entity(ies), including foreign entities (Intermediaries)

with the understanding that the Intermediary shall:

- directly or indirectly lend to, or invest in, other persons or entities identified in any manner whatsoever by or on behalf of the Company
(Ultimate Beneficiaries); or

- provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(vi) The Company has not received any funds from any other person(s) or entity(ies), including foreign entities (Funding Party) with the
understanding (whether recorded in writing or otherwise) that the Company shall:

- directly or indirectly lend to, or invest in, other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party or

- provide any guarantee, security or the like to or on behalf of the Funding Party.

(vii) The Company has not entered into any transaction which is not recorded into the books of accounts that has been surrendered or disclosed
as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions
of the Income Tax Act, 1961).

(viii) The Company has not been declared a 'Wilful Defaulter' by any bank or financial institution or government or any government
authority.

(ix) The Company has complied with the number of layers prescribed under Section 2(87) of the Act read with the Companies (Restriction on
Number of Layers) Rules, 2017.

(x) No scheme of arrangements has been approved by the Competent Authority in term of Sections 230 to 237 of the Companies Act, 2013,
during the year and previous year.

(xi) The Company does not have any borrowings from banks or financial institutions against security of its current assets.

(xii) The title deeds of the immovable properties owned by the Company are held in the name of Company.

Notes:

a. no significant change (25% or more) in financial year 2025-26 in comparison to financial year 2024-25

b. due to increase in unsecured borrowings and losses

c. due to lower operating profits & increased interest cost

d. due to lower net operating profit

e. due to increased cost of goods sold

f. due to negative average working capital

54. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code
on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 ('Labour Codes') which consolidate 29 (twenty-
nine) existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes,
amongst other things, introduces changes including a uniform definition of wages. The incremental impact of these changes, assessed by the
Company, on the basis of the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, has
been accounted for accordingly. Once Central / State Rules are notified by the Government upon all the aspects of the Labour Codes, the Company
shall evaluate additional impact, if any, on the measurement of employee benefits and would provide appropriate accounting effect.

55. In October 2023, the Company received notice from the International Court of Arbitration, Paris ("ICC") intimating commencement of
an Arbitration proceeding pursuant to the request filed by Apotex Inc., claiming an amount of US$ 118.14 million towards outsized
alleged losses plus interest thereon under the Collaboration Agreement dated May 09, 2014 entered into between Apotex Inc. and the
Company. The said agreement was subsequently assigned and novated in favour of Panacea Biotec Pharma Limited ("PBPL") wholly
owned subsidiary of the Company. The Company submitted its response to the notice of arbitration rebutting the claims raised by Apotex
citing novation of the said agreement in favour of PBPL. Apotex subsequently filed request for joinder of PBPL in the said arbitration
proceedings, raising the claim against the Company and PBPL aggregating to US$163.24 million, which was objected by the Company
and PBPL. The management believed that the Company and / or PBPL is not in breach of its obligations and the claims filed by Apotex are
frivolous, unsubstantiated, premised on fundamental factual misstatements and incorrect legal assumptions regarding the Collaboration

Agreement and contrary to the overwhelming facts and evidence. Both sides appointed their respective arbitrators, and these arbitrators
nominated the third arbitrator as the chairman of the arbitration tribunal. PBPL also filed a request for arbitration before ICC with respect
to dispute with Apotex raising a claim of US$ 9.90 million towards PBPL's share of profit from sale of authorized generic products sold by
Apotex during financial year 2022-23 in USA under the terms of the said Collaboration Agreement and the settlement agreement signed
among the Parties including the innovator company. ICC combined the two arbitrations proceedings and thereafter the initial arbitration
proceedings were started. During financial year 2025-26, both the parties have executed a Settlement Agreement dated July 3, 2025
recording full and final settlement of the disputes forming part of the arbitration. Pursuant to the settlement Apotex has inter-alia, agreed
to pay US$ 5.0 million in 2 tranches (US$ 2.5 million within 30 days and US$ 2.5 million upon receipt of final USFDA approval of the ANDA).
The Arbitration Tribunal has made the Consent Award on September 12, 2025 in this regard.

56. The Ministry of Corporate Affairs (MCA) has prescribed a new requirement for companies under the proviso to Rule 3(1) of the Companies (Accounts)
Rules, 2014 inserted by the Companies (Accounts) Amendment Rules, 2021 requiring companies, which uses accounting software for maintaining
its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an
edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be
disabled.

Management has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and
the same has operated throughout the year for all relevant transactions recorded in the software, except that the audit trail feature was not enabled
at the database level for accounting software to log any direct data changes, used for maintenance of all accounting records by the Company.

Further, the audit trail feature has not been tampered with during the year and the audit trail, to the extent maintained in the prior years, has been
preserved by the Company as per the statutory requirements for the record retention.

57. In accordance with Ind AS 108, 'Operating Segments', the Company has disclosed the segment information in the consolidated financial statements.
Accordingly, the segment information is given in the audited consolidated financial statements of the Group for the year ended March 31,2026.

58. 0.00 under "? in million” represents amount less than ?50,000 and 0.00 under units represents units less than 50,000. Further, the figures
shown in the tables may not exactly add up due to rounding off. Previous year figures have been regrouped, reclassified wherever considered
necessary. The impact of such reclassification/regrouping is not material to the financial statements.

59. There are no other subsequent events that occurred after reporting date.